vs
Side-by-side financial comparison of Mind Medicine (MindMed) Inc. (DFTX) and TaoWeave, Inc. (TWAV). Click either name above to swap in a different company.
Mind Medicine (MindMed) Inc. is the larger business by last-quarter revenue ($906.0K vs $622.0K, roughly 1.5× TaoWeave, Inc.). TaoWeave, Inc. runs the higher net margin — -448.2% vs -2634.0%, a 2185.8% gap on every dollar of revenue. On growth, TaoWeave, Inc. posted the faster year-over-year revenue change (10.5% vs -16.1%).
Definium Therapeutics, Inc., formerly known as MindMed, is a New York-based biotechnology company that is currently developing clinical and therapeutic applications for psychedelic and, more broadly, psychoplastogenic drugs.
DFTX vs TWAV — Head-to-Head
Income Statement — Q4 FY2023 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $906.0K | $622.0K |
| Net Profit | $-23.9M | $-2.8M |
| Gross Margin | — | 47.1% |
| Operating Margin | -2450.8% | -126.4% |
| Net Margin | -2634.0% | -448.2% |
| Revenue YoY | -16.1% | 10.5% |
| Net Profit YoY | -386.7% | -215.4% |
| EPS (diluted) | $-0.58 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $622.0K | ||
| Q3 25 | — | $601.0K | ||
| Q2 25 | — | $592.0K | ||
| Q1 25 | — | $622.0K | ||
| Q4 24 | — | $563.0K | ||
| Q3 24 | — | $578.0K | ||
| Q2 24 | — | $611.0K | ||
| Q1 24 | — | $626.0K |
| Q4 25 | — | $-2.8M | ||
| Q3 25 | — | $-2.3M | ||
| Q2 25 | — | $-605.0K | ||
| Q1 25 | — | $-672.0K | ||
| Q4 24 | — | $-884.0K | ||
| Q3 24 | — | $-1.0M | ||
| Q2 24 | — | $-983.0K | ||
| Q1 24 | — | $-1.1M |
| Q4 25 | — | 47.1% | ||
| Q3 25 | — | 40.6% | ||
| Q2 25 | — | 38.5% | ||
| Q1 25 | — | 40.0% | ||
| Q4 24 | — | 24.0% | ||
| Q3 24 | — | 13.7% | ||
| Q2 24 | — | 19.6% | ||
| Q1 24 | — | -0.5% |
| Q4 25 | — | -126.4% | ||
| Q3 25 | — | -133.4% | ||
| Q2 25 | — | -115.4% | ||
| Q1 25 | — | -111.1% | ||
| Q4 24 | — | -164.8% | ||
| Q3 24 | — | -185.5% | ||
| Q2 24 | — | -166.6% | ||
| Q1 24 | — | -189.1% |
| Q4 25 | — | -448.2% | ||
| Q3 25 | — | -381.0% | ||
| Q2 25 | — | -102.2% | ||
| Q1 25 | — | -108.0% | ||
| Q4 24 | — | -157.0% | ||
| Q3 24 | — | -179.9% | ||
| Q2 24 | — | -160.9% | ||
| Q1 24 | — | -181.5% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $-0.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $99.7M | $2.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $78.1M | $7.0M |
| Total Assets | $124.5M | $8.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $2.3M | ||
| Q3 25 | — | $3.7M | ||
| Q2 25 | — | $10.8M | ||
| Q1 25 | — | $4.3M | ||
| Q4 24 | — | $5.0M | ||
| Q3 24 | — | $5.6M | ||
| Q2 24 | — | $5.9M | ||
| Q1 24 | — | — |
| Q4 25 | — | $7.0M | ||
| Q3 25 | — | $9.8M | ||
| Q2 25 | — | $11.3M | ||
| Q1 25 | — | $3.4M | ||
| Q4 24 | — | $4.0M | ||
| Q3 24 | — | $4.7M | ||
| Q2 24 | — | $5.1M | ||
| Q1 24 | — | $4.4M |
| Q4 25 | — | $8.2M | ||
| Q3 25 | — | $10.9M | ||
| Q2 25 | — | $13.1M | ||
| Q1 25 | — | $4.8M | ||
| Q4 24 | — | $5.3M | ||
| Q3 24 | — | $6.0M | ||
| Q2 24 | — | $6.3M | ||
| Q1 24 | — | $5.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-20.6M | $-744.0K |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-744.0K | ||
| Q3 25 | — | $-1.6M | ||
| Q2 25 | — | $-37.0K | ||
| Q1 25 | — | $-680.0K | ||
| Q4 24 | — | $-255.0K | ||
| Q3 24 | — | $-911.0K | ||
| Q2 24 | — | $-1.6M | ||
| Q1 24 | — | $-630.0K |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
